Bausch + Lomb (BLCO) versus The Competition Head-To-Head Contrast

Bausch + Lomb (NYSE:BLCO) is one of 95 publicly-traded companies in the “Medical Services” industry, but how does it contrast to its rivals? We will compare Bausch + Lomb to similar businesses based on the strength of its risk, profitability, valuation, earnings, institutional ownership, analyst recommendations and dividends.

Profitability

This table compares Bausch + Lomb and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bausch + Lomb	-7.50%	2.62%	1.28%
Bausch + Lomb Competitors	-747.65%	-29.71%	-13.76%

Earnings & Valuation

This table compares Bausch + Lomb and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Bausch + Lomb	$4.79 billion	-$317.00 million	-11.66
Bausch + Lomb Competitors	$12.84 billion	$234.98 million	1.76

Bausch + Lomb’s rivals have higher revenue and earnings than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Insider and Institutional Ownership

11.1% of Bausch + Lomb shares are owned by institutional investors. Comparatively, 57.3% of shares of all “Medical Services” companies are owned by institutional investors. 0.2% of Bausch + Lomb shares are owned by insiders. Comparatively, 12.9% of shares of all “Medical Services” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Volatility and Risk

Bausch + Lomb has a beta of 0.56, indicating that its share price is 44% less volatile than the S&P 500. Comparatively, Bausch + Lomb’s rivals have a beta of 1.24, indicating that their average share price is 24% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Bausch + Lomb and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch + Lomb	1	8	4	0	2.23
Bausch + Lomb Competitors	418	2236	4784	151	2.62

Bausch + Lomb currently has a consensus target price of $15.54, indicating a potential upside of 29.46%. As a group, “Medical Services” companies have a potential upside of 443.18%. Given Bausch + Lomb’s rivals stronger consensus rating and higher possible upside, analysts plainly believe Bausch + Lomb has less favorable growth aspects than its rivals.

Summary

Bausch + Lomb rivals beat Bausch + Lomb on 10 of the 13 factors compared.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.